Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts

Previous Episode: BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges

Next Episode: Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma

In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:

Overall approach to treatmentUse of JAK inhibitors for treating myelofibrosisTreating patients with low plateletsDefining JAK inhibitor failureUnmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches

Presenters:

John Mascarenhas, MD
Professor of Medicine

Icahn School of Medicine at Mount Sinai

Director, Adult Leukemia Program

Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute

New York, New York

Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Enterprise Senior Vice President, Atrium Health

President, Enterprise Cancer Service Line

Vice Dean for Cancer Programs, Wake Forest University School of Medicine

Professor of Medicine, Wake Forest University School of Medicine

Winston-Salem, North Carolina

Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts

CCO Oncology Podcast